Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
2020 · Nano Today · 72 citations
https://doi.org/10.1016/j.nantod.2020.101025
F
Fengqi Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
233
Papers
3.2K
Citations
30
h-index
55
i10-index
Fengqi Zhou is an academic researcher from Kunming University of Science and Technology. The author has contributed to research in topics: Plasmonic and Surface Plasmon Research & Metamaterials and Metasurfaces Applications & Adaptive Control of Nonlinear Systems. The author has an h-index of 30, co-authored 199 publications.
ORCID: 0000-0003-4070-8153Papers by this author
worksEngineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer
2021 · Advanced Materials · 63 citations
https://doi.org/10.1002/adma.202102668
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma
2022 · Oncogene · 26 citations
https://doi.org/10.1038/s41388-022-02570-w
Effect of intravenous esketamine on postoperative sleep disturbance, anxiety, and depression in elderly patients undergoing laparoscopic abdominal surgery: a randomized controlled trial
2025 · BMC Geriatrics · 13 citations
https://doi.org/10.1186/s12877-025-05787-y
Incidence of and risk factors for suspected and definitive glaucoma after bilateral congenital cataract surgery: a 5-year follow-up
2023 · British Journal of Ophthalmology · 10 citations
https://doi.org/10.1136/bjo-2022-322589
Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma
2025 · Oncogene · 3 citations
https://doi.org/10.1038/s41388-025-03454-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat